Guardant Health’s Shield Adcom questions largely in-line, says UBS

UBS analyst Elizabeth Garcia tells investors in a research note that there were no meaningful surprises in the first read of the FDA’s advisory committee meeting materials for Guardant Health’s Shield colorectal cancer screening test. UBS says voting and panel questions are largely in line with the firm’s questions, though discussion of screening interval is not included. UBS made no change to its Buy rating or $32 price target.